KY Pharmaceuticals

Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma experienced thirteen insider trading transactions over the past ninety days, totaling over 564,000 dollars in sales. Key executives, including the CEO and CFO, executed planned divestments. These activities follow a recent earnings report that exceeded expectations, while the stock price has declined nearly eighteen percent during this period.
Ticker: CBIO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Crescent Biopharma, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.3
Brumm Joshua T Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
289.07
Quantity 43,522 +13.5%
Value US$2,104,439
1.4
McNeill Jonathan President and COO Officer
Transaction date
Planned sale
Price
385.02
Quantity 61,391 -25.0%
Value US$2,649,660
2.3
Joshua T Brumm Officer; Director Executive Director
Transaction date
Proposed sale
Price
469.88
Quantity 21,939
Value US$520,716
1.4
Jonathan McNeill Officer Officer
Transaction date
Proposed sale
Price
17.18
Quantity 4,415
Value US$75,850
Im Ellie Eunkyung Chief Medical Officer Officer
Transaction date
Planned sale
Price
17.90
Quantity 623 -2.8%
Value US$11,152
Lynch Ryan See Remarks Officer
Transaction date
Planned sale
Price
17.90
Quantity 240 -1.7%
Value US$4,296
Pinkas Jan Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.90
Quantity 658 -3.0%
Value US$11,778
Bispham Barbara Harlin See Remarks Officer
Transaction date
Planned sale
Price
17.90
Quantity 620 -3.2%
Value US$11,098
2.3
Brumm Joshua T Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
17.90
Quantity 1,610 -0.6%
Value US$28,819
1.4
McNeill Jonathan President and COO Officer
Transaction date
Planned sale
Price
17.90
Quantity 731 -0.5%
Value US$13,085
3.0
Scalzo Richard William Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.90
Quantity 568 -2.8%
Value US$10,167
2.3
Joshua T Brumm Officer; Director Executive Director
Transaction date
Proposed sale
Price
18.80
Quantity 1,771
Value US$33,295
1.4
Jonathan McNeill Officer Officer
Transaction date
Proposed sale
Price
18.80
Quantity 804
Value US$15,115
3.3
Fairmount Funds Management LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.50
Quantity 853,450 +31.1%
Value US$12,375,025
3.0
Scalzo Richard William Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.99
Quantity 1,112 -5.2%
Value US$20,005
Pinkas Jan Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.99
Quantity 1,288 -5.5%
Value US$23,171
Lynch Ryan See Remarks Officer
Transaction date
Planned sale
Price
17.99
Quantity 465 -3.2%
Value US$8,365
Bispham Barbara Harlin See Remarks Officer
Transaction date
Planned sale
Price
17.99
Quantity 1,218 -5.9%
Value US$21,912
Im Ellie Eunkyung Chief Medical Officer Officer
Transaction date
Planned sale
Price
17.99
Quantity 1,219 -5.2%
Value US$21,930
2.3
Brumm Joshua T Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
17.99
Quantity 42,305 -13.1%
Value US$761,067
1.4
McNeill Jonathan President and COO Officer
Transaction date
Planned sale
Price
17.99
Quantity 20,549 -12.9%
Value US$369,677
3.3
Fairmount Funds Management LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.41
Quantity 1,360,000 +98.0%
Value US$18,237,600
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
0.27
Quantity 115,000 +20.3%
Value US$30,716
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
0.25
Quantity 190,000 +50.6%
Value US$48,108
3.4
Hahn Brian M. SVP Finance, CFO Officer
Transaction date
Purchase
Price
0.25
Quantity 17,500 +32.9%
Value US$4,335
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
1.38
Quantity 30,403 +8.8%
Value US$41,956
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
1.38
Quantity 35,000 +11.3%
Value US$48,300
3.4
Hahn Brian M. SVP Finance, CFO Officer
Transaction date
Sale
Price
1.95
Quantity 3,700 -6.5%
Value US$7,215
3.4
Hahn Brian M. Officer Officer
Transaction date
Proposed sale
Price
1.96
Quantity 4,313
Value US$8,453
2.6
JUNIUS DANIEL M Non-Executive Director
Transaction date
Purchase
Price
1.56
Quantity 30,000 +47.4%
Value US$46,800
2.4
Johnson Bruce S SVP & Chief Commercial Officer Officer
Transaction date
Purchase
Price
1.57
Quantity 13,500 +10.8%
Value US$21,195
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.12
Quantity 1,351,092 -37.7%
Value US$4,213,786
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.12
Quantity 1,648,908 -37.7%
Value US$5,142,614
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.26
Quantity 293,645 -7.6%
Value US$958,428
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.26
Quantity 358,371 -7.6%
Value US$1,169,687
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.76
Quantity 32,139 -0.8%
Value US$88,659
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.76
Quantity 39,223 -0.8%
Value US$108,201
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.91
Quantity 45,930 -1.2%
Value US$133,643
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.91
Quantity 56,054 -1.2%
Value US$163,100
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.99
Quantity 78,730 -1.9%
Value US$235,411
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
2.99
Quantity 96,084 -1.9%
Value US$287,301
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.02
Quantity 54,645 -1.3%
Value US$165,028
2.4
SANDELL SCOTT D Large shareholder
Transaction date
Sale
Price
3.02
Quantity 66,690 -1.3%
Value US$201,404
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
2.25
Quantity 110,000 +55.0%
Value US$247,500
2.6
JUNIUS DANIEL M Non-Executive Director
Transaction date
Purchase
Price
1.87
Quantity 20,000 +46.2%
Value US$37,400
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
1.66
Quantity 100,000 +100.0%
Value US$166,000
3.5
Rock Edwin Chief Medical Officer Officer
Transaction date
Purchase
Price
1.43
Quantity 100,000 New position
Value US$143,000
3.3
PEARSON TIMOTHY R Non-Executive Director
Transaction date
Purchase
Price
1.29
Quantity 19,400 +369.5%
Value US$25,026
3.3
Semerjian Harout Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.29
Quantity 25,000 New position
Value US$32,250
3.4
Hahn Brian M. SVP Finance, CFO Officer
Transaction date
Purchase
Price
1.06
Quantity 20,000 +54.3%
Value US$21,200
3.8
Girard Armand SVP, Chief Business Officer Officer
Transaction date
Purchase
Price
1.05
Quantity 6,500 +28.7%
Value US$6,825
3.8
Magnani John L. SVP of Research, CSO Officer
Transaction date
Purchase
Price
1.17
Quantity 45,045 +14.0%
Value US$52,703
3.4
Hahn Brian M. SVP Finance, CFO Officer
Transaction date
Sale
Price
1.09
Quantity 2,917 -7.3%
Value US$3,180
3.8
Magnani John L. SVP of Research, CSO Officer
Transaction date
Sale
Price
1.09
Quantity 3,227 -1.0%
Value US$3,517
3.8
Girard Armand SVP, Chief Business Officer Officer
Transaction date
Sale
Price
1.09
Quantity 2,339 -9.4%
Value US$2,550
0.5
Andrews Patricia S Non-Executive Director
Transaction date
Purchase
Price
2.05
Quantity 40,000 +761.9%
Value US$82,000
2.3
King Rachel K. President, CEO Executive Director
Transaction date
Planned sale
Price
3.91
Quantity 84,176 -19.1%
Value US$329,128
4.0
BVF PARTNERS L P/IL Large shareholder
Transaction date
Purchase
Price
2.60
Quantity 86,090 +15.8%
Value US$223,834
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-18 2026-09-18 PlS Planned sale
2.3
Brumm Joshua T

Chief Executive Officer

Executive Director
43,522 +13.5%
289.07
US$2,104,439 		43,522 +13.5% 289.07 US$2,104,439
2026-09-18 2026-09-18 PlS Planned sale
1.4
McNeill Jonathan

President and COO

Officer
61,391 -25.0%
385.02
US$2,649,660 		61,391 -25.0% 385.02 US$2,649,660
2026-09-17 2026-09-18 PrS Proposed sale
2.3
Joshua T Brumm

Officer; Director

Executive Director
21,939
469.88
US$520,716 		21,939 469.88 US$520,716
2026-09-17 2026-09-18 PrS Proposed sale
1.4
Jonathan McNeill

Officer

Officer
4,415
17.18
US$75,850 		4,415 17.18 US$75,850
2026-09-18 2026-09-16 PlS Planned sale
Im Ellie Eunkyung

Chief Medical Officer

Officer
623 -2.8%
17.90
US$11,152 		623 -2.8% 17.90 US$11,152
2026-09-18 2026-09-16 PlS Planned sale
Lynch Ryan

See Remarks

Officer
240 -1.7%
17.90
US$4,296 		240 -1.7% 17.90 US$4,296
2026-09-18 2026-09-16 PlS Planned sale
Pinkas Jan

Chief Scientific Officer

Officer
658 -3.0%
17.90
US$11,778 		658 -3.0% 17.90 US$11,778
2026-09-18 2026-09-16 PlS Planned sale
Bispham Barbara Harlin

See Remarks

Officer
620 -3.2%
17.90
US$11,098 		620 -3.2% 17.90 US$11,098
2026-09-18 2026-09-16 PlS Planned sale
2.3
Brumm Joshua T

Chief Executive Officer

Executive Director
1,610 -0.6%
17.90
US$28,819 		1,610 -0.6% 17.90 US$28,819
2026-09-18 2026-09-16 PlS Planned sale
1.4
McNeill Jonathan

President and COO

Officer
731 -0.5%
17.90
US$13,085 		731 -0.5% 17.90 US$13,085
2026-09-18 2026-09-16 PlS Planned sale
3.0
Scalzo Richard William

Chief Financial Officer

Officer
568 -2.8%
17.90
US$10,167 		568 -2.8% 17.90 US$10,167
2026-09-16 2026-09-16 PrS Proposed sale
2.3
Joshua T Brumm

Officer; Director

Executive Director
1,771
18.80
US$33,295 		1,771 18.80 US$33,295
2026-09-16 2026-09-16 PrS Proposed sale
1.4
Jonathan McNeill

Officer

Officer
804
18.80
US$15,115 		804 18.80 US$15,115
2026-07-20 2026-07-16 B Purchase
3.3
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
853,450 +31.1%
14.50
US$12,375,025 		853,450 +31.1% 14.50 US$12,375,025
2026-06-23 2026-06-22 PlS Planned sale
3.0
Scalzo Richard William

Chief Financial Officer

Officer
1,112 -5.2%
17.99
US$20,005 		1,112 -5.2% 17.99 US$20,005
2026-06-23 2026-06-22 PlS Planned sale
Pinkas Jan

Chief Scientific Officer

Officer
1,288 -5.5%
17.99
US$23,171 		1,288 -5.5% 17.99 US$23,171
2026-06-23 2026-06-22 PlS Planned sale
Lynch Ryan

See Remarks

Officer
465 -3.2%
17.99
US$8,365 		465 -3.2% 17.99 US$8,365
2026-06-23 2026-06-22 PlS Planned sale
Bispham Barbara Harlin

See Remarks

Officer
1,218 -5.9%
17.99
US$21,912 		1,218 -5.9% 17.99 US$21,912
2026-06-23 2026-06-22 PlS Planned sale
Im Ellie Eunkyung

Chief Medical Officer

Officer
1,219 -5.2%
17.99
US$21,930 		1,219 -5.2% 17.99 US$21,930
2026-06-23 2026-06-22 PlS Planned sale
2.3
Brumm Joshua T

Chief Executive Officer

Executive Director
42,305 -13.1%
17.99
US$761,067 		42,305 -13.1% 17.99 US$761,067
2026-06-23 2026-06-22 PlS Planned sale
1.4
McNeill Jonathan

President and COO

Officer
20,549 -12.9%
17.99
US$369,677 		20,549 -12.9% 17.99 US$369,677
2025-12-08 2025-12-04 B Purchase
3.3
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
1,360,000 +98.0%
13.41
US$18,237,600 		1,360,000 +98.0% 13.41 US$18,237,600
2024-08-09 2024-08-08 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
260,873 -4.0%
0.19
US$50,009 		260,873 -4.0% 0.19 US$50,009
2024-08-09 2024-08-07 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
61,488 -0.9%
0.18
US$11,197 		61,488 -0.9% 0.18 US$11,197
2024-08-07 2024-08-06 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
55,732 -0.8%
0.18
US$10,188 		55,732 -0.8% 0.18 US$10,188
2024-08-07 2024-08-05 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
164,523 -2.4%
0.19
US$30,996 		164,523 -2.4% 0.19 US$30,996
2024-08-05 2024-08-02 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
286,200 -4.0%
0.20
US$57,354 		286,200 -4.0% 0.20 US$57,354
2024-08-05 2024-08-01 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
63,564 -0.9%
0.22
US$13,743 		63,564 -0.9% 0.22 US$13,743
2024-07-30 2024-07-30 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
756,835 -9.5%
0.22
US$167,185 		756,835 -9.5% 0.22 US$167,185
2024-07-30 2024-07-29 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
363,949 -4.4%
0.24
US$85,637 		363,949 -4.4% 0.24 US$85,637
2024-07-30 2024-07-26 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
258,335 -3.0%
0.24
US$62,440 		258,335 -3.0% 0.24 US$62,440
2024-06-24 2024-06-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
115,000 +20.3%
0.27
US$30,716 		115,000 +20.3% 0.27 US$30,716
2024-06-24 2024-06-20 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
190,000 +50.6%
0.25
US$48,108 		190,000 +50.6% 0.25 US$48,108
2024-06-20 2024-06-18 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
17,500 +32.9%
0.25
US$4,335 		17,500 +32.9% 0.25 US$4,335
2023-09-25 2023-09-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
30,403 +8.8%
1.38
US$41,956 		30,403 +8.8% 1.38 US$41,956
2023-09-25 2023-09-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
35,000 +11.3%
1.38
US$48,300 		35,000 +11.3% 1.38 US$48,300
2023-05-18 2023-05-17 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
3,700 -6.5%
1.95
US$7,215 		3,700 -6.5% 1.95 US$7,215
2023-05-17 2023-05-17 PrS Proposed sale
3.4
Hahn Brian M.

Officer

Officer
4,313
1.96
US$8,453 		4,313 1.96 US$8,453
2023-05-11 2023-05-10 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
30,000 +47.4%
1.56
US$46,800 		30,000 +47.4% 1.56 US$46,800
2023-05-09 2023-05-08 B Purchase
2.4
Johnson Bruce S

SVP & Chief Commercial Officer

Officer
13,500 +10.8%
1.57
US$21,195 		13,500 +10.8% 1.57 US$21,195
2023-02-28 2023-02-24 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
100,000 +1.2%
1.70
US$170,000 		100,000 +1.2% 1.70 US$170,000
2023-02-23 2023-02-23 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.4%
1.75
US$350,760 		200,000 +2.4% 1.75 US$350,760
2023-02-23 2023-02-22 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
150,000 +1.8%
1.79
US$268,995 		150,000 +1.8% 1.79 US$268,995
2023-02-23 2023-02-21 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
50,000 +0.6%
1.85
US$92,500 		50,000 +0.6% 1.85 US$92,500
2023-02-17 2023-02-17 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.5%
1.71
US$341,000 		200,000 +2.5% 1.71 US$341,000
2023-02-17 2023-02-16 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
315,266 +4.2%
1.68
US$531,129 		315,266 +4.2% 1.68 US$531,129
2023-02-17 2023-02-15 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
1,000,000 +15.2%
2.16
US$2,155,800 		1,000,000 +15.2% 2.16 US$2,155,800
2023-02-13 2023-02-09 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
11,451 +0.2%
3.24
US$37,123 		11,451 +0.2% 3.24 US$37,123
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,351,092 -37.7%
3.12
US$4,213,786 		1,351,092 -37.7% 3.12 US$4,213,786
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,648,908 -37.7%
3.12
US$5,142,614 		1,648,908 -37.7% 3.12 US$5,142,614
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
293,645 -7.6%
3.26
US$958,428 		293,645 -7.6% 3.26 US$958,428
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
358,371 -7.6%
3.26
US$1,169,687 		358,371 -7.6% 3.26 US$1,169,687
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
32,139 -0.8%
2.76
US$88,659 		32,139 -0.8% 2.76 US$88,659
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
39,223 -0.8%
2.76
US$108,201 		39,223 -0.8% 2.76 US$108,201
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
45,930 -1.2%
2.91
US$133,643 		45,930 -1.2% 2.91 US$133,643
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
56,054 -1.2%
2.91
US$163,100 		56,054 -1.2% 2.91 US$163,100
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
78,730 -1.9%
2.99
US$235,411 		78,730 -1.9% 2.99 US$235,411
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
96,084 -1.9%
2.99
US$287,301 		96,084 -1.9% 2.99 US$287,301
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
54,645 -1.3%
3.02
US$165,028 		54,645 -1.3% 3.02 US$165,028
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
66,690 -1.3%
3.02
US$201,404 		66,690 -1.3% 3.02 US$201,404
2022-12-27 2022-12-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
110,000 +55.0%
2.25
US$247,500 		110,000 +55.0% 2.25 US$247,500
2022-11-18 2022-11-17 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
20,000 +46.2%
1.87
US$37,400 		20,000 +46.2% 1.87 US$37,400
2022-11-16 2022-11-15 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 +100.0%
1.66
US$166,000 		100,000 +100.0% 1.66 US$166,000
2022-11-16 2022-11-14 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 New position
1.43
US$143,000 		100,000 New position 1.43 US$143,000
2022-11-14 2022-11-11 B Purchase
3.3
PEARSON TIMOTHY R
Non-Executive Director
19,400 +369.5%
1.29
US$25,026 		19,400 +369.5% 1.29 US$25,026
2022-11-14 2022-11-11 B Purchase
3.3
Semerjian Harout

Chief Executive Officer

Executive Director
25,000 New position
1.29
US$32,250 		25,000 New position 1.29 US$32,250
2022-11-14 2022-11-11 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
20,000 +54.3%
1.06
US$21,200 		20,000 +54.3% 1.06 US$21,200
2022-11-14 2022-11-11 B Purchase
3.8
Girard Armand

SVP, Chief Business Officer

Officer
6,500 +28.7%
1.05
US$6,825 		6,500 +28.7% 1.05 US$6,825
2022-11-14 2022-11-11 B Purchase
3.8
Magnani John L.

SVP of Research, CSO

Officer
45,045 +14.0%
1.17
US$52,703 		45,045 +14.0% 1.17 US$52,703
2022-03-10 2022-03-09 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
2,917 -7.3%
1.09
US$3,180 		2,917 -7.3% 1.09 US$3,180
2022-03-10 2022-03-09 S Sale
3.8
Magnani John L.

SVP of Research, CSO

Officer
3,227 -1.0%
1.09
US$3,517 		3,227 -1.0% 1.09 US$3,517
2022-03-10 2022-03-09 S Sale
3.8
Girard Armand

SVP, Chief Business Officer

Officer
2,339 -9.4%
1.09
US$2,550 		2,339 -9.4% 1.09 US$2,550
2021-11-18 2021-11-16 B Purchase
0.5
Andrews Patricia S
Non-Executive Director
40,000 +761.9%
2.05
US$82,000 		40,000 +761.9% 2.05 US$82,000
2020-12-30 2020-12-28 PlS Planned sale
2.3
King Rachel K.

President, CEO

Executive Director
84,176 -19.1%
3.91
US$329,128 		84,176 -19.1% 3.91 US$329,128
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
86,090 +15.8%
2.60
US$223,834 		86,090 +15.8% 2.60 US$223,834

See older Crescent Biopharma, Inc. insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Crescent Biopharma, Inc. history with Plus

Billed monthly · Cancel anytime

Explore more

More insider trading research around Crescent Biopharma, Inc.

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity